抗C1结构域致病性抗体抑制剂与凝血因子VIII复合物的结构
本研究解析了A组抗C1结构域抑制剂2A9与B结构域缺失的生物工程fVIII构建体ET3i的复合物结构。2A9表位与C1结构域的三个表面环及A3结构域直接接触,其中C1环也参与fVIII与血管性血友病因子界面。ET3i:2A9复合物中C2结构域发生20 Å向外移位的新构象变化。
要点
- 抗C1结构域抑制剂2A9与fVIII的C1和A3结构域多个表位直接接触。
- 2A9表位的C1环同时也是fVIII与血管性血友病因子的潜在界面。
- 复合物中C2结构域向外移位20 Å,提示抑制剂诱导构象变化。
核心结论
- 首次报道抗C1结构域抗体抑制剂与治疗活性fVIII构建体的复合物结构。
研究设计与样本
- 结构生物学研究,解析2A9与B结构域缺失生物工程fVIII构建体ET3i的复合物结构。
主要发现
- 2A9表位与C1结构域三个表面环Lys2065-Trp2070、Arg2150-Tyr2156和Lys2110-Trp2112直接接触。
- 2A9还与A3结构域Phe1743-Tyr1748环及Asn1810 N-连接糖基化接触。
- ET3i:2A9复合物中C2结构域向外移位20 Å,发生大型新构象变化。
临床怎么用
- 结构认识fVIII免疫原性可能有助于开发更有效、安全的fVIII替代疗法。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antibody inhibitor development in hemophilia A represents the most significant complication resulting from factor VIII (fVIII) replacement therapy. Recent studies have demonstrated that epitopes present in the C1 domain contribute to a pathogenic inhibitor response. In this study, we report the structure of a group A anti-C1 domain inhibitor, termed 2A9, in complex with a B domain-deleted, bioengineered fVIII construct (ET3i). The 2A9 epitope forms direct contacts to the C1 domain at 3 different surface loops consisting of Lys2065-Trp2070, Arg2150-Tyr2156, and Lys2110-Trp2112. Additional contacts are observed between 2A9 and the A3 domain, including the Phe1743-Tyr1748 loop and the N-linked glycosylation at Asn1810. Most of the C1 domain loops in the 2A9 epitope also represent a putative interface between fVIII and von Willebrand factor. Lastly, the C2 domain in the ET3i:2A9 complex adopts a large, novel conformational change, translocating outward from the structure of fVIII by 20 Å. This study reports the first structure of an anti-C1 domain antibody inhibitor and the first fVIII:inhibitor complex with a therapeutically active fVIII construct. Further structural understanding of fVIII immunogenicity may result in the development of more effective and safe fVIII replacement therapies.
引用
- Gish JS, Jarvis L, Childers KC, et al. Structure of blood coagulation factor VIII in complex with an anti-C1 domain pathogenic antibody inhibitor. Blood. 2021. PMID: 33529335. doi:10.1182/blood.2020008940
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。